Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Acellular Tissue Engineered Vessel (ATEV)
BIOLOGICAL
3 trials
Sponsors
Humacyte, Inc.
Conditions
End Stage Renal Disease (ESRD)
End Stage Renal Disease on Dialysis
Trauma
Vascular Diseases
Vascular System Injury
Phase 2
Humacyte Acellular Tissue Engineered Vessel (ATEV) in Patients With Vascular Trauma
Completed
NCT03005418
Humacyte, Inc.
Trauma, Vascular System Injury
Start: 2018-09-01
End: 2026-05-15
Updated: 2026-07-29
Phase 3
To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodialysis
Active, not recruiting
NCT05908084
Humacyte, Inc.
End Stage Renal Disease (ESRD)
Start: 2023-09-07
End: 2028-06-01
Updated: 2026-06-26
Unknown Phase
Individual Patient Expanded Access for Acellular Tissue Engineered Vessel (ATEV) for Vascular Disease and Dialysis Access
NCT07141641
Humacyte, Inc.
End Stage Renal Disease on Dialysis, Vascular Diseases
Updated: 2026-09-15
Related Papers
Bioengineered human blood vessels to treat hospital-acquired vascular complications.
2025-09-08
Bioengineered Human Arteries for the Repair of Vascular Injuries.
2025-02-01
18 citations